GENOSS showcases 3D-printed spinal implant lineup at Korean spine conference

South Korean medical device company GENOSS presented its lineup of 3D-printed spinal implants at the 27th Spring Congress of the Korean Society of Spine New Technology, held July 4 at Seoul St. Mary's Hospital. The company exhibited products including 3D-printed cervical cages, lumbar cages, cervical plates, and screws, alongside its regenerative medicine offerings such as BRIGHT PDRN Inj. and MONALISA PN/PH dressings. GENOSS reported that surgeons engaged on the porous structures and osteointegration characteristics of the 3D-printed cages, with technical discussions covering application methods for cervical versus lumbar surgical environments. The company confirmed it will expand its 3D lumbar cage lineup in the second half of 2026 and is pursuing regulatory approval and supply arrangements for a 3D anterior cervical plate and screw system.

This event fits the familiar pattern of implant manufacturers moving from subtractive manufacturing and traditional casting to metal AM for porous cage structures optimized for bone ingrowth. The spinal implant segment has been one of the more commercially grounded adopters of metal AM - titanium LPBF cages have been in clinical use for over a decade, with companies like Stryker, NuVasive, and ZimVie having established AM-based portfolios. GENOSS, while smaller than those global players, is positioning its 3D-printed spine lineup as a differentiated offering in the Korean and broader Asian orthopedic market. The key competitive variable is no longer whether to use AM, but how well the porous lattice design and surface finish promote osteointegration - a materials-and-qualification question rather than a machine-performance question. The company's simultaneous push into regenerative medicine indicates a strategy of combining implant hardware with biologic adjuncts, which could strengthen its positioning in orthopedic surgery suites.

For GENOSS, the practical next step is converting the surgeon feedback from this conference into design iterations and securing Korean MFDS clearance for its expanded lumbar and cervical product lines. The spinal implant AM market is mature enough that novelty alone does not move adoption - the company must demonstrate consistent manufacturing quality, competitive pricing against established implant OEMs, and a clear clinical evidence package. This is a routine product-line expansion by a regional player; it does not signal a market shift, but it does show that metal AM for spinal implants has become standard manufacturing infrastructure rather than a competitive differentiator.